Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE

Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE

Copyright © 2019. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 205(2019) vom: 15. Aug., Seite 43-48
1. Verfasser: Ye, Yujin (VerfasserIn)
Weitere Verfasser: Wu, Tianfu, Zhang, Ting, Han, Jie, Habazi, Deena, Saxena, Ramesh, Mohan, Chandra
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Autoantibodies Oxidized lipid Systemic lupus erythematosus (SLE) 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine Complement C3 Complement C4 Immunoglobulin G Immunoglobulin M Linoleic Acids mehr... Linoleic Acids, Conjugated Lipoproteins, LDL Phospholipid Ethers malondialdehyde-low density lipoprotein, human oxidized low density lipoprotein 9-hydroxy-10,12-octadecadienoic acid 15514-85-9 Malondialdehyde 4Y8F71G49Q 13-hydroxy-9,11-octadecadienoic acid 5204-88-6 DNA 9007-49-2
LEADER 01000caa a22002652 4500
001 NLM296945544
003 DE-627
005 20250225074312.0
007 cr uuu---uuuuu
008 231225s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2019.05.004  |2 doi 
028 5 2 |a pubmed25n0989.xml 
035 |a (DE-627)NLM296945544 
035 |a (NLM)31075396 
035 |a (PII)S1521-6616(19)30088-9 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ye, Yujin  |e verfasserin  |4 aut 
245 1 0 |a Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE 
264 1 |c 2019 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 20.04.2020 
500 |a Date Revised 20.04.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2019. Published by Elsevier Inc. 
520 |a BACKGROUND: Here, we explore the serum levels of anti-oxidized lipid autoantibodies as well as immune complexes in patients with SLE and determine their correlation with disease 
520 |a METHODS: Serum levels of oxidized-LDL immune complexes, autoantibodies to dsDNA, ox-LDL, MDA-LDL, 9-HODE, 13-HODE and POVPC were detected by ELISA in 64 SLE patients and 9 healthy controls 
520 |a RESULTS: Active SLE patients exhibited increased serum levels of autoantibodies compared to healthy controls, including anti-MDA-LDL-IgG (p = .003), anti-ox-LDL-IgG (p = .004), anti-9-HODE-IgG (p = .001), anti-13-HODE-IgG (p = .0003), anti-POVPC-IgG (p = .001) and ox-LDL-IC (p = .003). Serum anti-ox-LDL-IgG was positively correlated with SLEDAI (r = 0.34; p = .01), and negatively with C3 (r = -0.40; p = .01). Anti-9-HODE-IgG and anti-POVPC-IgG were positively correlated with SLEDAI and negatively with C4 
520 |a CONCLUSIONS: Active SLE patients exhibit significantly increased serum levels of IgG anti-oxidized-lipid autoantibodies. Coordinated elevation of oxidized lipids, autoantibodies to these lipids, and immune complexes of these lipid-antibody components could potentially serve as pathogenic drivers and serum markers of SLE disease activity 
650 4 |a Journal Article 
650 4 |a Autoantibodies 
650 4 |a Oxidized lipid 
650 4 |a Systemic lupus erythematosus (SLE) 
650 7 |a 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Complement C3  |2 NLM 
650 7 |a Complement C4  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Immunoglobulin M  |2 NLM 
650 7 |a Linoleic Acids  |2 NLM 
650 7 |a Linoleic Acids, Conjugated  |2 NLM 
650 7 |a Lipoproteins, LDL  |2 NLM 
650 7 |a Phospholipid Ethers  |2 NLM 
650 7 |a malondialdehyde-low density lipoprotein, human  |2 NLM 
650 7 |a oxidized low density lipoprotein  |2 NLM 
650 7 |a 9-hydroxy-10,12-octadecadienoic acid  |2 NLM 
650 7 |a 15514-85-9  |2 NLM 
650 7 |a Malondialdehyde  |2 NLM 
650 7 |a 4Y8F71G49Q  |2 NLM 
650 7 |a 13-hydroxy-9,11-octadecadienoic acid  |2 NLM 
650 7 |a 5204-88-6  |2 NLM 
650 7 |a DNA  |2 NLM 
650 7 |a 9007-49-2  |2 NLM 
700 1 |a Wu, Tianfu  |e verfasserin  |4 aut 
700 1 |a Zhang, Ting  |e verfasserin  |4 aut 
700 1 |a Han, Jie  |e verfasserin  |4 aut 
700 1 |a Habazi, Deena  |e verfasserin  |4 aut 
700 1 |a Saxena, Ramesh  |e verfasserin  |4 aut 
700 1 |a Mohan, Chandra  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 205(2019) vom: 15. Aug., Seite 43-48  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:205  |g year:2019  |g day:15  |g month:08  |g pages:43-48 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2019.05.004  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 205  |j 2019  |b 15  |c 08  |h 43-48